Search

Your search keyword '"Chauvierre, Cédric"' showing total 161 results
Start Over Author "Chauvierre, Cédric"
161 results on '"Chauvierre, Cédric"'

4. Erythrocyte-Inspired Discoidal Polymeric Nanoconstructs carrying Tissue Plasminogen Activator for the Enhanced Lysis of Blood Clots

Author

Colasuonno, Marianna, Palange, Anna Lisa, Aid, Rachida, Ferreira, Miguel, Mollica, Hilaria, Palomba, Roberto, Emdin, Michele, Del Sette, Massimo, Chauvierre, Cédric, Letourneur, Didier, and Decuzzi, Paolo

Subjects
Quantitative Biology - Quantitative Methods
Abstract

Tissue plasminogen activator (tPA) is the sole approved therapeutic molecule for the treatment of acute ischemic stroke. Yet, only a small percentage of patients could benefit from this life-saving treatment because of medical contraindications and severe side effects, including brain hemorrhage, associated with delayed administration. Here, a nano therapeutic agent is realized by directly associating the clinical formulation of tPA to the porous structure of soft discoidal polymeric nanoconstructs (tPA-DPNs). The porous matrix of DPNs protects tPA from rapid degradation, allowing tPA-DPNs to preserve over 70 % of the tPA original activity after 3 h of exposure to serum proteins. Under dynamic conditions, tPA-DPNs dissolve clots more efficiently than free tPA, as demonstrated in a microfluidic chip where clots are formed mimicking in vivo conditions. At 60 min post treatment initiation, the clot area reduces by half (57 + 8 %) with tPA-DPNs, whereas a similar result (56 + 21 %) is obtained only after 90 min for free tPA. In murine mesentery venules, the intravenous administration of 2.5 mg/kg of tPA-DPNs resolves almost 90 % of the blood clots, whereas a similar dose of free tPA successfully recanalize only about 40 % of the treated vessels. At about 1/10 of the clinical dose (1.0 mg/kg), tPA-DPNs still effectively dissolve 70 % of the clots, whereas free tPA works efficiently only on 16 % of the vessels. In vivo, discoidal tPA-DPNs outperform the lytic activity of 200 nm spherical tPA-coated nanoconstructs in terms of both percentage of successful recanalization events and clot area reduction. The conjugation of tPA with preserved lytic activity, the deformability and blood circulating time of DPNs together with the faster blood clot dissolution would make tPA-DPNs a promising nanotool for enhancing both potency and safety of thrombolytic therapies.

Published
2019

6. First-in-human study of 99mTc-labeled fucoidan, a SPECT tracer targeting P-selectin.

Author

Oostveen, Reindert F., Zheng, Kang H., Kaiser, Yannick, Nurmohamed, Nick S., Kroon, Jeffrey, de Wit, Tim C., Poel, Edwin, Aerts, Joel, Rouzet, Francois, Stroes, Erik S. G., Letourneur, Didier, Verberne, Hein J., Chauvierre, Cédric, and Ståhle, Mia R.

Abstract

Background: Activation of endothelial cells and platelets in atherothrombosis is characterized by upregulation of P-selectin. As a consequence, P-selectin represents a potential target for molecular imaging to identify thrombosis at an early stage. Fucoidan is a polysaccharide ligand extracted from brown algae with nanomolar affinity for P-selectin. This first-in-human study evaluated in healthy volunteers the safety, whole-body biodistribution, and dosimetry of 99mTc-fucoidan (Good Manufacturing Practices grade). We also investigated whether we could observe binding of 99mTc-fucoidan to human thrombi ex vivo and in vivo. In ten healthy volunteers, conjugate whole-body scans were performed up to 24 h following intravenous injection of 99mTc-fucoidan (370 MBq). Moreover, 99mTc-fucoidan uptake in ex vivo human thrombi (n = 11) was measured by gamma counting. Additionally, three patients with a newly diagnosed deep vein thrombosis (DVT) were subjected to 99mTc-fucoidan SPECT/CT imaging. Results: 99mTc-fucoidan was well tolerated in all participants without any drug-related adverse events. The total-body absorbed dose in males was comparable to females (0.012 ± 0.004 vs. 0.011 ± 0.005 mSv/MBq; p = 0.97). Gamma counting experiments demonstrated binding of tracer to ex vivo human thrombi that was 16% lower after blocking with a natural P-selectin ligand, Sialyl Lewis X. 99mTc-fucoidan demonstrated specific uptake at the thrombus site in one out of three scanned patients with DVT. Conclusions: 99mTc-Fucoidan has a favorable biodistribution and safety profile. 99mTc-fucoidan exhibited specific binding to human thrombi in both in vivo and ex vivo settings. Nonetheless, the in vivo results do not support further clinical investigation of 99mTc-fucoidan as an imaging modality for DVT. Other clinical implementations of a technetium− 99m-labeled P-selectin tracer should be considered. Trial registration: Clinicaltrials,NCT03422055.Registered 01/15/2018. URL: https://clinicaltrials.gov/study/NCT03422055Landelijk Trial Register, NL7739. Registered 4/2/2019. https://onderzoekmetmensen.nl/en/trial/26785 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Fucoidan

Author

Maire, Murielle, primary, Chollet, Lucas, additional, Rolland, Lydia, additional, Letourneur, Didier, additional, Chauvierre, Cédric, additional, and Chaubet, Frédéric, additional

Published
2019
Full Text
View/download PDF

22. Roadmap on Nanomedicine

Author

Decuzzi, Paolo, Peer, Dan, Di Mascolo, Daniele, Palange, Anna Lisa, Manghnani, Purnima Naresh, Moghimi, Seyed Moen, Farhangrazi, Z. Shadi, Howard, Kenneth A., Rosenblum, Daniel, Liang, Tingxizi, Chen, Zhaowei, Wang, Zejun, Zhu, Jun-Jie, Gu, Zhen, Korin, Netanel, Letourneur, Didier, Chauvierre, Cédric, van der Meel, Roy, Kiessling, Fabian, Lammers, Twan, Decuzzi, Paolo, Peer, Dan, Di Mascolo, Daniele, Palange, Anna Lisa, Manghnani, Purnima Naresh, Moghimi, Seyed Moen, Farhangrazi, Z. Shadi, Howard, Kenneth A., Rosenblum, Daniel, Liang, Tingxizi, Chen, Zhaowei, Wang, Zejun, Zhu, Jun-Jie, Gu, Zhen, Korin, Netanel, Letourneur, Didier, Chauvierre, Cédric, van der Meel, Roy, Kiessling, Fabian, and Lammers, Twan

Abstract

Since the launch of the Alliance for Nanotechnology in Cancer by the National Cancer Institute in the late 2004, several similar initiatives were promoted all over the globe with the intent to advance the diagnosis, treatment and prevention of cancer in the wake of Nanoscience and Nanotechnology. All this has encouraged scientists with diverse backgrounds to team up with one another, learn from each other, and generate new knowledge at the interface between engineering, physics, chemistry and biomedical sciences. Importantly, this new knowledge has been wisely channeled towards the development of novel diagnostic, imaging and therapeutic nano-systems, many of which are currently at different stages of clinical development. This roadmap collects eight brief articles elaborating on the interaction of nanomedicines with human biology; the biomedical and clinical applications of nanomedicines; and the importance of patient stratification in the development of future nanomedicines. The first article reports on the role of geometry and mechanical properties in nanomedicine rational design; while the second articulates on the interaction of nanomedicines with cells of the immune system and the third deals with exploiting endogenous molecules, such as albumin, to carry therapeutic agents. The second group of articles highlights the successful application of nanomedicines in the treatment of cancer with the optimal delivery of nucleic acids, diabetes with the sustained and controlled release of insulin, stroke by using thrombolytic particles and atherosclerosis with the development of targeted nanoparticles. Finally, the last contribution comments on how nanomedicine and theranostics could play a pivotal role in the development of personalized medicines. As this roadmap cannot cover the massive development of nanomedicine over the past 15 years, only a few major achievements are highlighted as the field progressively matures from the initial hype to the consolidation

Published
2021

25. Pharmaceutical Development and Safety Evaluation of a GMP-Grade Fucoidan for Molecular Diagnosis of Cardiovascular Diseases

Author

Chauvierre, Cédric, Aid-Launais, Rachida, Aerts, Joël, Chaubet, Frederic, Maire, Murielle, Chollet, Lucas, Rolland, Lydia, Bonafé, Roberta, Rossi, Silvia, Bussi, Simona, Cabella, Claudia, Dézsi, Laszlo, Fulop, Tamas, Szebeni, Janos, Chahid, Youssef, Zheng, Kang, Stroes, Erik, Le Guludec, Dominique, Rouzet, François, Letourneur, Didier, Laboratoire de Recherche Vasculaire Translationnelle (LVTS (UMR_S_1148 / U1148)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Université Sorbonne Paris Nord, Pharmacy, Radiology and Nuclear Medicine, Experimental Vascular Medicine, Vascular Medicine, ACS - Atherosclerosis & ischemic syndromes, Université Paris Diderot - Paris 7 (UPD7)-Université Paris 13 (UP13)-Institut National de la Santé et de la Recherche Médicale (INSERM), Fédération de Recherche en Imagerie Multimodalité [Paris] (UMS34 FRIM), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Bracco Research SpA, Bracco, Semmelweis University [Budapest, Hungary], Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), Service de Médecine Nucléaire [Paris 18eme], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
Male, regulatory toxicology, MESH: Rats, Swine, [SDV]Life Sciences [q-bio], Myocardial Reperfusion Injury, Article, MESH: Dose-Response Relationship, Drug, Drug Development, Polysaccharides, molecular diagnosis, Animals, scintigraphy, MESH: Animals, Rats, Wistar, MESH: Swine, ComputingMilieux_MISCELLANEOUS, MESH: Drug Development, Dose-Response Relationship, Drug, MESH: Molecular Weight, GMP-grade fucoidan, scintigraphy, regulatory toxicology, molecular diagnosis, GMP-grade fucoidan, Technetium, MESH: Rats, Wistar, MESH: Male, MESH: Myocardial Reperfusion Injury, Rats, Molecular Weight, Disease Models, Animal, P-Selectin, [SDV.SP.PG]Life Sciences [q-bio]/Pharmaceutical sciences/Galenic pharmacology, MESH: Polysaccharides, MESH: P-Selectin, MESH: Technetium, Female, Radiopharmaceuticals, MESH: Disease Models, Animal, MESH: Female, MESH: Radiopharmaceuticals
Abstract

The adhesion molecule P-selectin is present on the cell surface of both activated endothelium and activated platelets. The present study describes the pharmaceutical development, safety evaluation, and preclinical efficacy of a micro-dosed radiotracer. The macromolecular nanoscale assembly consisted of a natural compound made of a sulfated fucose-rich polysaccharides (fucoidan) and a radionuclide (technetium-99m) for the detection of P-selectin expression in cardiovascular diseases. After extraction and fractionation from brown seaweeds, the good manufacturing practice (GMP) production of a low molecular weight (LMW) fucoidan of 7 kDa was achieved and full physicochemical characterization was performed. The regulatory toxicology study in rats of the GMP batch of LMW fucoidan revealed no adverse effects up to 400 &mu, g/kg (&times, 500 higher than the expected human dose) and pseudoallergy was not seen as well. In a myocardial ischemia-reperfusion model in rats, the GMP-grade LMW fucoidan labeled with technetium-99m detected P-selectin upregulation in vivo. The present study supports the potential of using 99mTc-fucoidan as an imaging agent to detect activated endothelium in humans.

Published
2019

29. Roadmap on nanomedicine

Author

Decuzzi, Paolo, primary, Peer, Dan, additional, Mascolo, Daniele Di, additional, Palange, Anna Lisa, additional, Manghnani, Purnima Naresh, additional, Moghimi, S Moein, additional, Farhangrazi, Z Shadi, additional, Howard, Kenneth A, additional, Rosenblum, Daniel, additional, Liang, Tingxizi, additional, Chen, Zhaowei, additional, Wang, Zejun, additional, Zhu, Jun-Jie, additional, Gu, Zhen, additional, Korin, Netanel, additional, Letourneur, Didier, additional, Chauvierre, Cédric, additional, van der Meel, Roy, additional, Kiessling, Fabian, additional, and Lammers, Twan, additional

Published
2020
Full Text
View/download PDF

35. From design to the clinic: practical guidelines for translating cardiovascular nanomedicine

Author

Cicha, Iwona, Chauvierre, Cédric, Texier, Isabelle, Cabella, Claudia, Metselaar, Josbert M., Szebeni, János, Alexiou, Christoph, Rouzet, François, Storm, Gert, Stroes, Erik, Bruce, Donald, MacRitchie, Neil, Maffia, Pasquale, and Letourneur, Didier

Abstract

Cardiovascular diseases (CVD) account for nearly half of all deaths in Europe and almost 30% of global deaths. Despite the improved clinical management, cardiovascular mortality is predicted to rise in the next decades due to the increasing impact of aging, obesity, and diabetes. The goal of emerging cardiovascular nanomedicine is to reduce the burden of CVD using nanoscale medical products and devices. However, the development of novel multicomponent nano-sized products poses multiple technical, ethical, and regulatory challenges, which often obstruct their road to successful approval and use in clinical practice. This review discusses the rational design of nanoparticles, including safety considerations and regulatory issues, and highlights the steps needed to achieve efficient clinical translation of promising nanomedicinal products for cardiovascular applications.

Published
2018

36. From design to the clinic: practical guidelines for translating cardiovascular nanomedicine

Author

Afd Pharmaceutics, Pharmaceutics, Cicha, Iwona, Chauvierre, Cédric, Texier, Isabelle, Cabella, Claudia, Metselaar, Josbert M, Szebeni, János, Dézsi, László, Alexiou, Christoph, Rouzet, François, Storm, Gert, Stroes, Erik, Bruce, Donald, MacRitchie, Neil, Maffia, Pasquale, Letourneur, Didier, Afd Pharmaceutics, Pharmaceutics, Cicha, Iwona, Chauvierre, Cédric, Texier, Isabelle, Cabella, Claudia, Metselaar, Josbert M, Szebeni, János, Dézsi, László, Alexiou, Christoph, Rouzet, François, Storm, Gert, Stroes, Erik, Bruce, Donald, MacRitchie, Neil, Maffia, Pasquale, and Letourneur, Didier

Published
2018

38. Erythrocyte-Inspired Discoidal Polymeric Nanoconstructs Carrying Tissue Plasminogen Activator for the Enhanced Lysis of Blood Clots

Author

Colasuonno, Marianna, primary, Palange, Anna Lisa, additional, Aid, Rachida, additional, Ferreira, Miguel, additional, Mollica, Hilaria, additional, Palomba, Roberto, additional, Emdin, Michele, additional, Del Sette, Massimo, additional, Chauvierre, Cédric, additional, Letourneur, Didier, additional, and Decuzzi, Paolo, additional

Published
2018
Full Text
View/download PDF

39. Comparative analysis of nanosystems’ effects on human endothelial and monocytic cell functions

Author

Matuszak, Jasmin, primary, Dörfler, Philipp, additional, Lyer, Stefan, additional, Unterweger, Harald, additional, Juenet, Maya, additional, Chauvierre, Cédric, additional, Alaarg, Amr, additional, Franke, Danielle, additional, Almer, Gunter, additional, Texier, Isabelle, additional, Metselaar, Josbert M., additional, Prassl, Ruth, additional, Alexiou, Christoph, additional, Mangge, Harald, additional, Letourneur, Didier, additional, and Cicha, Iwona, additional

Published
2018
Full Text
View/download PDF

41. Fucoidans in Nanomedicine

Author

Chollet, Lucas, primary, Saboural, Pierre, additional, Chauvierre, Cédric, additional, Villemin, Jean-Noël, additional, Letourneur, Didier, additional, and Chaubet, Frédéric, additional

Published
2016
Full Text
View/download PDF

42. Nanoparticles for intravascular applications: physicochemical characterization and cytotoxicity testing

Author

Matuszak, Jasmin, primary, Baumgartner, Jens, additional, Zaloga, Jan, additional, Juenet, Maya, additional, da Silva, Acarília Eduardo, additional, Franke, Danielle, additional, Almer, Gunter, additional, Texier, Isabelle, additional, Faivre, Damien, additional, Metselaar, Josbert M, additional, Navarro, Fabrice P, additional, Chauvierre, Cédric, additional, Prassl, Ruth, additional, Dézsi, László, additional, Urbanics, Rudolf, additional, Alexiou, Christoph, additional, Mangge, Harald, additional, Szebeni, János, additional, Letourneur, Didier, additional, and Cicha, Iwona, additional

Published
2016
Full Text
View/download PDF

46. Ultrasmall superparamagnetic iron oxide nanoparticles coated with fucoidan for molecular MRI of intraluminal thrombus

Author

Suzuki, Michimasa, primary, Bachelet-Violette, Laure, additional, Rouzet, François, additional, Beilvert, Anne, additional, Autret, Gwennhael, additional, Maire, Murielle, additional, Menager, Christine, additional, Louedec, Liliane, additional, Choqueux, Christine, additional, Saboural, Pierre, additional, Haddad, Oualid, additional, Chauvierre, Cédric, additional, Chaubet, Frédéric, additional, Michel, Jean-Baptiste, additional, Serfaty, Jean-Michel, additional, and Letourneur, Didier, additional

Published
2015
Full Text
View/download PDF

47. Purification of a Low Molecular Weight Fucoidan for SPECT Molecular Imaging of Myocardial Infarction

Author

Saboural, Pierre, primary, Chaubet, Frédéric, additional, Rouzet, Francois, additional, Al-Shoukr, Faisal, additional, Azzouna, Rana, additional, Bouchemal, Nadia, additional, Picton, Luc, additional, Louedec, Liliane, additional, Maire, Murielle, additional, Rolland, Lydia, additional, Potier, Guy, additional, Guludec, Dominique, additional, Letourneur, Didier, additional, and Chauvierre, Cédric, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results